APLS - Public offerings

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants, including the exercise in full by the underwriters of their option to purchase an additional 833,333 shares. The exercise of the option to purchase additional shares increased the amount of gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by Apellis, to approximately $402.5 million. The public offering consisted of 4,007,936 shares of common stock at the publ

WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 3,174,603 shares of its common stock at a public offering price of $63.00 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 2,380,956 shares of its common stock at a public offering price of $62.9999 per pre-funded warrant, for total gross proceeds of approximately $350 million, before deducting underwriting discounts and commissions and offering expenses payable by Apellis. The purchase price of each pre-funded warrant e

WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an underwritten public offering of $300 million of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof). All of the shares of common stock and pre-funded warrants are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount equal to 15% of the securities offered in the public offering. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C.

WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,117,021 shares at the public offering price of $47.00 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Apellis to 8,563,830 shares and increased the amount of gross proceeds, before deducting underwriting discounts and commissions and expenses payable by Apellis, t

WALTHAM, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 7,446,809 shares of its common stock at a public offering price of $47.00 per share, for total gross proceeds of $350 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares in the offering are being sold by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 1,117,021 additional shares of its common stock at the public offering price, less the underwriting discounts an

WALTHAM, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an underwritten public offering of $300 million of its common stock. All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C. are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no

WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,312,500 shares at the public offering price of $40.00 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Apellis to 10,062,500 shares and increased the amount of gross proceeds, before deducting underwriting discounts and commissions and expenses payable by Apellis, t

WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 8,750,000 shares of its common stock at a public offering price of $40.00 per share, for total gross proceeds of $350 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares in the offering are being sold by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 1,312,500 additional shares of its common stock at the public offering price, less the underwriting discounts and

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an underwritten public offering of $300 million of its common stock. All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C. are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no a

WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotiated exchange transactions (the "Exchange Transactions") with certain holders of its 3.500% Convertible Senior Notes due 2026 (the "Notes"). In the Exchange Transactions, the holders exchanged approximately $201.1 million in aggregate principal amount of Notes and Apellis issued an aggregate of 5,992,217 shares of its common stock. The shares of Apellis' common stock issued in the exchanges were not registered under the Securities Act of 1933, as amended

WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotiated exchange transactions (the “Exchange Transactions”) with certain holders of its 3.500% Convertible Senior Notes due 2026 issued in September 2019 (the “Notes”). In the Exchange Transactions, the holders exchanged approximately $126.1 million in aggregate principal amount of Notes and Apellis issued an aggregate of 3,906,869 shares of its common stock. The shares of Apellis’ common stock issued in the exchanges were not registered under the Securit